<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="brief-report" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Med.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Medicine</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Med.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2296-858X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmed.2025.1740090</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Brief Research Report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Histopathological characterization of inflammatory interparietal involvement in frontal fibrosing alopecia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Gonzalez Ca&#x00F1;ete</surname>
<given-names>Marta</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3111184"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rodr&#x00ED;guez-Villa Lario</surname>
<given-names>Ana</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3086832"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vega D&#x00ED;ez</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3107083"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>V&#x00E9;lez Velazquez</surname>
<given-names>Mar&#x00ED;a Dolores</given-names>
</name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ricart Vaya</surname>
<given-names>Jose Maria</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3044164"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>G&#x00F3;mez Zubiaur</surname>
<given-names>Alba</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/3038217"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x0026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &#x0026; editing</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Instituto m&#x00E9;dico ricart</institution>, <city>Madrid</city>, <country country="es">Spain</country></aff>
<aff id="aff2"><label>2</label><institution>Department of Dermatology, Hospital Universitario Principe de Asturias</institution>, <city>Alcala de Henares</city>, <country country="es">Spain</country></aff>
<aff id="aff3"><label>3</label><institution>Department of Pathology, Hospital Universitario Principe de Asturias</institution>, <city>Alcala de Henares</city>, <country country="es">Spain</country></aff>
<author-notes>
<corresp id="c001"><label>&#x002A;</label>Correspondence: Marta Gonzalez Ca&#x00F1;ete, <email xlink:href="mailto:martagoncan@me.com">martagoncan@me.com</email></corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-01-12">
<day>12</day>
<month>01</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2025</year>
</pub-date>
<volume>12</volume>
<elocation-id>1740090</elocation-id>
<history>
<date date-type="received">
<day>05</day>
<month>11</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>09</day>
<month>12</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>12</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2026 Gonzalez Ca&#x00F1;ete, Rodr&#x00ED;guez-Villa Lario, Vega D&#x00ED;ez, V&#x00E9;lez Velazquez, Ricart Vaya and G&#x00F3;mez Zubiaur.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Gonzalez Ca&#x00F1;ete, Rodr&#x00ED;guez-Villa Lario, Vega D&#x00ED;ez, V&#x00E9;lez Velazquez, Ricart Vaya and G&#x00F3;mez Zubiaur</copyright-holder>
<license>
<ali:license_ref start_date="2026-01-12">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Introduction</title>
<p>Frontal fibrosing alopecia (FFA) may involve the interparietal area; however, histopathologic features in this site remain undefined.</p>
</sec>
<sec>
<title>Objective</title>
<p>The objective of the study was to histopathologically characterize inflammatory interparietal involvement in patients with FFA in real-world practice.</p>
</sec>
<sec>
<title>Methods</title>
<p>A descriptive, retrospective study enrolled patients with FFA who developed interparietal inflammatory findings. Patients underwent two interparietal biopsies; samples were assessed under a uniform protocol, which included follicular counts, inflammatory infiltrate features, scar tissue, vacuolar degeneration (VD) of the follicular epithelium, epithelial or stromal (E/S) clefting, concentric lamellar fibroplasia (CLF), and sebaceous glands (SGs).</p>
</sec>
<sec>
<title>Results</title>
<p>A total of 12 females (mean age: 64.25&#x202F;years) were included. Following dermatopathologic review, six patients were classified as having crown-area FFA (CA-FFA), four patients as having fibrosing alopecia with a pattern distribution (FAPD), and two patients as having indeterminate cicatricial alopecia. CA-FFA showed greater structural loss with scar tissue and sebaceous gland reduction, whereas FAPD showed a miniaturization-dominant profile and increased catagen/telogen hairs. Patients with a biopsy suggestive of CA-FFA more often had a diffuse clinical pattern, were older, had a longer disease duration, and had approximately twice as much occipital involvement than as those in the FAPD group.</p>
</sec>
<sec>
<title>Discussion/Conclusion</title>
<p>Given that FFA produces greater structural disruption than FAPD, our results raise the question of whether these conditions are overlapping entities or part of the same process that has progressed. Further studies in patients with FFA and FAPD are needed to elucidate the role of androgenetic factors in addition to lymphohistiocytic infiltrate and perifollicular lamellar fibrosis.</p>
</sec>
</abstract>
<kwd-group>
<kwd>AGA</kwd>
<kwd>androgenetic alopecia</kwd>
<kwd>CA-FFA</kwd>
<kwd>FAPD</kwd>
<kwd>FFA</kwd>
<kwd>FFA with crown-area involvement</kwd>
<kwd>fibrosing alopecia with a pattern distribution</kwd>
<kwd>frontal fibrosing alopecia</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was not received for this work and/or its publication.</funding-statement>
</funding-group>
<counts>
<fig-count count="1"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="14"/>
<page-count count="7"/>
<word-count count="3704"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Dermatology</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec1">
<label>1</label>
<title>Introduction</title>
<p>Frontal fibrosing alopecia (FFA) is an acquired lymphocytic scarring alopecia of increasing incidence worldwide. It is clinically characterized by a progressive frontotemporal hairline recession, often accompanied by eyebrow alopecia. Occasionally, FFA may present with interparietal involvement, a feature that Kossard already reported in 1994 (<xref ref-type="bibr" rid="ref1">1</xref>). This involvement may reflect coexistence of FFA with androgenetic alopecia (AGA) (<xref ref-type="bibr" rid="ref2">2</xref>), fibrosing alopecia with a pattern distribution (FAPD) (<xref ref-type="bibr" rid="ref3">3</xref>), or lichen planopilaris (LPP) (<xref ref-type="bibr" rid="ref2">2</xref>), or it may be due to the disease itself (<xref ref-type="bibr" rid="ref4 ref5 ref6">4&#x2013;6</xref>), which we refer to as FFA with crown-area involvement (CA-FFA). Trichoscopic evaluations of patients with FFA and interparietal involvement have identified a diffuse fibrotic pattern in up to 68% of patients (<xref ref-type="bibr" rid="ref6">6</xref>). However, in the absence of histopathologic confirmation, it remains unclear how many cases truly correspond to CA-FFA or represent an overlap with other alopecia types. To the best of our knowledge, no previous histopathological studies have specifically addressed interparietal involvement in FFA. Clarifying these histopathologic patterns may assist in distinguishing CA-FFA from overlapping forms of scarring alopecia, improving diagnostic accuracy.</p>
</sec>
<sec sec-type="materials|methods" id="sec2">
<label>2</label>
<title>Materials and methods</title>
<p>We conducted a descriptive and retrospective study enrolling patients with a previous clinical and trichoscopic diagnosis of FFA, in whom interparietal inflammatory findings were observed during follow-up. Participants were evaluated at the Trichology Unit of our center between July and September 2021.</p>
<p>Inflammatory findings were defined as clinical and/or trichoscopic evidence of interparietal involvement and/or symptomatology in that area, including reduced hair density, pruritus, or signs of perifollicular inflammation or scarring, such as perifollicular erythema, perifollicular hyperkeratosis, or loss of follicular ostia.</p>
<p>Two 4-mm interparietal punch biopsies guided by trichoscopy were performed in all patients. The specimens were fixed in formaldehyde, processed in vertical and horizontal sections, and stained with hematoxylin and eosin. The samples were analyzed by the same expert dermatopathologist, following the same protocol. The number of terminal follicles (TFs), miniaturized follicles (MFs), the presence and characteristics of the inflammatory infiltrate, scar tissue, the presence or absence of pigmentary molds, vacuolar degeneration of the follicular epithelium, epithelial or stromal clefting, concentric lamellar fibroplasia, and sebaceous glands were studied in all samples. Informed written consent was obtained from all patients.</p>
<p>This study aimed to characterize the histopathology in the interparietal region of patients with FFA and clinical and/or trichoscopic findings suggestive of inflammation in the interparietal region and/or symptoms in the said location in real clinical practice.</p>
</sec>
<sec sec-type="results" id="sec3">
<label>3</label>
<title>Results</title>
<p>A total of 12 Caucasian females with a previous diagnosis of FFA and with a mean age of 64.25&#x202F;years (range: 49&#x2013;83) were included. Comorbid conditions included hypothyroidism (<italic>n</italic>&#x202F;=&#x202F;5), cutaneous lichen planus (<italic>n</italic>&#x202F;=&#x202F;1), breast cancer (<italic>n</italic>&#x202F;=&#x202F;1), rosacea (<italic>n</italic>&#x202F;=&#x202F;1), psoriasis (<italic>n</italic>&#x202F;=&#x202F;1), and genital lichen sclerosus (<italic>n</italic>&#x202F;=&#x202F;1).</p>
<p>Following blinded dermatopathologic review, six patients were classified as having findings consistent with CA-FFA (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), four patients as having FAPD (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), and two patients could not be assigned to either group; however, they both had a cicatricial alopecia with lymphocytic infiltrates. Patients were classified as FAPD if biopsies showed an increased number of vellus hairs, an increase in terminal follicles in catagen and telogen, and a lower terminal-to-vellus ratio (<xref ref-type="bibr" rid="ref7">7</xref>), and they were classified as CA-FFA if biopsies showed a higher number of follicular scars, more vacuolar degeneration of the follicular epithelium, a greater presence of follicular clefts, and fewer arrector pili muscles (<xref ref-type="bibr" rid="ref7">7</xref>).</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Hematoxylin&#x2013;eosin (H&#x0026;E), transverse and horizontal sections. <bold>(A)</bold> CA-FFA (patient 1): terminal anagen follicles with absence of vellus follicles and absent sebaceous glands, associated with scar tissue and a superficial peri-infundibular lymphocytic infiltrate. <bold>(B)</bold> FAPD (patient 11): both terminal and vellus/miniaturized follicles, some with superficial lymphocytic infiltrates, together with concentric lamellar fibroplasia.</p>
</caption>
<graphic xlink:href="fmed-12-1740090-g001.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Microscopic images of tissue sections stained with hematoxylin and eosin. Panel A shows two skin sections with hair follicles visible, characterized by layered structure and cellular details. Panel B displays a dense arrangement of glandular structures, highlighting circular formations. The colors range from pink to purple, indicating various tissue types and cellular components.</alt-text>
</graphic>
</fig>
<p>Detailed histopathologic findings are shown in <xref ref-type="table" rid="tab1">Table 1</xref>. Scar tissue and concentric lamellar fibroplasia were observed consistently across the groups. The inflammatory infiltrate was variable and generally mild to moderate, most often superficial (peri)infundibular, and was absent in some samples. Vacuolar degeneration of the follicular epithelium was uncommon (observed in a single CA-FFA case), and epithelial&#x2013;stromal clefting occurred infrequently, exclusively within CA-FFA. Sebaceous glands were typically absent or deeply reduced in CA-FFA, reduced but present in FAPD, and focally reduced/normal in indeterminate cases. FAPD biopsies contained more vellus/miniaturized hairs with a shift of terminal follicles toward catagen/telogen, whereas CA-FFA showed greater structural loss.</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Histopathologic findings in interparietal biopsies.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Patient</th>
<th align="center" valign="top">Total follicles</th>
<th align="center" valign="top">TF</th>
<th align="center" valign="top">V/M&#x202F;F</th>
<th align="center" valign="top">TF anagen</th>
<th align="center" valign="top">TF telogen</th>
<th align="center" valign="top">TF catagen</th>
<th align="left" valign="top">Inflammatory infiltrate</th>
<th align="center" valign="top">Scar tissue</th>
<th align="center" valign="top">PM</th>
<th align="center" valign="top">VD</th>
<th align="center" valign="top">E/S C</th>
<th align="center" valign="top">CLF</th>
<th align="center" valign="top">SG</th>
<th align="left" valign="top">Dx</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">1</td>
<td align="center" valign="middle">13</td>
<td align="center" valign="middle">13</td>
<td align="center" valign="middle">0</td>
<td align="center" valign="middle">12</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">0</td>
<td align="left" valign="top">Infund.<break/>mod.</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="left" valign="middle">CA-FFA</td>
</tr>
<tr>
<td align="left" valign="middle">2</td>
<td align="center" valign="middle">14</td>
<td align="center" valign="middle">12</td>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">14</td>
<td align="center" valign="middle">0</td>
<td align="center" valign="middle">0</td>
<td align="left" valign="top">None</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2193;&#x2193;</td>
<td align="left" valign="middle">CA-FFA</td>
</tr>
<tr>
<td align="left" valign="middle">3</td>
<td align="center" valign="middle">21</td>
<td align="center" valign="middle">17</td>
<td align="center" valign="middle">4</td>
<td align="center" valign="middle">19</td>
<td align="center" valign="middle">0</td>
<td align="center" valign="middle">2</td>
<td align="left" valign="top">M/VF, mild</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2193;</td>
<td align="left" valign="middle">FAPD</td>
</tr>
<tr>
<td align="left" valign="middle">4</td>
<td align="center" valign="middle">27</td>
<td align="center" valign="middle">22</td>
<td align="center" valign="middle">5</td>
<td align="center" valign="middle">25</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">1</td>
<td align="left" valign="top">TF and M/VF peri-infund. Mild&#x2013;mod.</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2193;</td>
<td align="left" valign="middle">FAPD</td>
</tr>
<tr>
<td align="left" valign="middle">5</td>
<td align="center" valign="middle">19</td>
<td align="center" valign="middle">14</td>
<td align="center" valign="middle">3</td>
<td align="center" valign="middle">18</td>
<td align="center" valign="middle">0</td>
<td align="center" valign="middle">1</td>
<td align="left" valign="top">Perifollicular sup. mild</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2193;</td>
<td align="left" valign="middle">NE<sup>1</sup></td>
</tr>
<tr>
<td align="left" valign="middle">6</td>
<td align="center" valign="middle">28</td>
<td align="center" valign="middle">6</td>
<td align="center" valign="middle">22</td>
<td align="center" valign="middle">20</td>
<td align="center" valign="middle">5</td>
<td align="center" valign="middle">3</td>
<td align="left" valign="top">None</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2193;</td>
<td align="left" valign="middle">FAPD</td>
</tr>
<tr>
<td align="left" valign="middle">7</td>
<td align="center" valign="middle">34</td>
<td align="center" valign="middle">29</td>
<td align="center" valign="middle">5</td>
<td align="center" valign="middle">34</td>
<td align="center" valign="middle">0</td>
<td align="center" valign="middle">0</td>
<td align="left" valign="top">TF and M/VF peri-infund. mild</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2193;</td>
<td align="left" valign="middle">CA-FFA</td>
</tr>
<tr>
<td align="left" valign="middle">8</td>
<td align="center" valign="middle">23</td>
<td align="center" valign="middle">21</td>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">22</td>
<td align="center" valign="middle">0</td>
<td align="center" valign="middle">1</td>
<td align="left" valign="top">Peri-infund. mild</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="left" valign="middle">CA-FFA</td>
</tr>
<tr>
<td align="left" valign="middle">9</td>
<td align="center" valign="middle">22</td>
<td align="center" valign="middle">19</td>
<td align="center" valign="middle">3</td>
<td align="center" valign="middle">19</td>
<td align="center" valign="middle">0</td>
<td align="center" valign="middle">0</td>
<td align="left" valign="top">None</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="left" valign="middle">CA-FFA</td>
</tr>
<tr>
<td align="left" valign="middle">10</td>
<td align="center" valign="middle">18</td>
<td align="center" valign="middle">18</td>
<td align="center" valign="middle">0</td>
<td align="center" valign="middle">17</td>
<td align="center" valign="middle">0</td>
<td align="center" valign="middle">1</td>
<td align="left" valign="top">Sup. mod.</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="left" valign="middle">CA-FFA</td>
</tr>
<tr>
<td align="left" valign="middle">11</td>
<td align="center" valign="middle">34</td>
<td align="center" valign="middle">22</td>
<td align="center" valign="middle">12</td>
<td align="center" valign="middle">32</td>
<td align="center" valign="middle">0</td>
<td align="center" valign="middle">2</td>
<td align="left" valign="top">M/VF sup. mild</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2193;</td>
<td align="left" valign="middle">FAPD</td>
</tr>
<tr>
<td align="left" valign="middle">12</td>
<td align="center" valign="middle">26</td>
<td align="center" valign="middle">24</td>
<td align="center" valign="middle">2</td>
<td align="center" valign="middle">21</td>
<td align="center" valign="middle">0</td>
<td align="center" valign="middle">5</td>
<td align="left" valign="top">Perivascular infiltrate/sup.</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">&#x2212;</td>
<td align="center" valign="middle">+</td>
<td align="center" valign="middle">&#x2193; (focal)</td>
<td align="left" valign="middle">NE<sup>2</sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>TF, terminal follicles; V/MF, vellus or miniaturized follicles; PM, pigmented molds; VD, vacuolar degeneration of the follicular epithelium; E/S C, epithelial or stromal clefting, CLF, concentric lamellar fibroplasia; SG, sebaceous glands; Dx, diagnosis; +/&#x2212;, present/absent; sup., superficial; mod., moderate; &#x2193;, reduced; &#x2193;&#x2193;, markedly reduced. NE<sup>1</sup>: cicatricial alopecia with terminal follicles and some vellus follicles, preservation of sebaceous glands, and mild superficial perifollicular lymphocytic infiltrates. NE<sup>2</sup>: cicatricial alopecia with increased catagen follicles, concentric lamellar fibroplasia in some terminal follicles, and mild perifollicular lymphocytic infiltrate.</p>
</table-wrap-foot>
</table-wrap>
<p>Patients classified as CA-FFA were older (mean age: 70 vs. 57&#x202F;years in FAPD) and had longer median disease duration (9 vs. 3&#x202F;years). Clinical patterns of FFA in the study population were as follows: in the CA-FFA group (<italic>n</italic>&#x202F;=&#x202F;6), two patients exhibited Type 1 patterns and four patients exhibited Type 2 patterns; in the FAPD group (<italic>n</italic>&#x202F;=&#x202F;4), two patients exhibited Type 1 patterns, one patient exhibited Type 2 patterns, and one patient exhibited Type 3 patterns; and in the indeterminate group (<italic>n</italic>&#x202F;=&#x202F;2), one patient exhibited Type 1 patterns and one patient exhibited Type 2 patterns. Overall, diffuse or Type 2 patterns were observed in 66.7% of CA-FFA patients, compared with only 25% of FAPD patients.</p>
<p>Occipital involvement was present in 50% of CA-FFA patients and 25% of FAPD patients; all patients had eyebrow alopecia, and 50% in both groups had body hair involvement. Preauricular wrinkling was the most frequent accompanying facial manifestation across all groups. The majority of participants exhibited a diffuse pattern of clinical interparietal involvement, with the exception of one patient classified as CA-FFA, whose case prompted a reconsideration of the diagnosis, since she exhibited macroscopically visible alopecia plaques, raising the possibility of an overlap between FFA and LPP. Interparietal pruritus was reported by 83% of CA-FFA patients and 50% of FAPD patients. Demographic and clinical characteristics are shown in <xref ref-type="table" rid="tab2">Table 2</xref>. In terms of trichoscopy, the majority of patients in the FAPD group showed evidence of hair miniaturization. The most frequent finding across all groups was perifollicular desquamation.</p>
<table-wrap position="float" id="tab2">
<label>Table 2</label>
<caption>
<p>Demographic and clinical characteristics (per patient).</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Patient</th>
<th align="center" valign="top">Age (years)</th>
<th align="center" valign="top">Disease duration (years)</th>
<th align="left" valign="top">Comorbidities</th>
<th align="left" valign="top">Clinical pattern (Type 1/2/3)</th>
<th align="left" valign="top">Eyebrow alopecia</th>
<th align="left" valign="top">Occipital involvement</th>
<th align="left" valign="top">Body hair involvement</th>
<th align="left" valign="top">Interparietal involvement type</th>
<th align="left" valign="top">Interparietal pruritus</th>
<th align="left" valign="top">Accompanying features<sup>&#x002A;</sup></th>
<th align="left" valign="top">Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">1</td>
<td align="center" valign="top">73</td>
<td align="center" valign="top">6</td>
<td align="left" valign="top">Hypothyroidism</td>
<td align="left" valign="top">Type 1</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">Diffuse</td>
<td align="left" valign="top">No</td>
<td align="left" valign="top">Preauricular wrinkling</td>
<td align="left" valign="top">CA-FFA</td>
</tr>
<tr>
<td align="left" valign="top">2</td>
<td align="center" valign="top">83</td>
<td align="center" valign="top">12</td>
<td align="left" valign="top">Hypothyroidism</td>
<td align="left" valign="top">Type 2</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">No</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">Plaques</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">Preauricular wrinkling and frontal vein prominence</td>
<td align="left" valign="top">CA-FFA</td>
</tr>
<tr>
<td align="left" valign="top">3</td>
<td align="center" valign="top">54</td>
<td align="center" valign="top">2</td>
<td align="left" valign="top">Cutaneous lichen planus</td>
<td align="left" valign="top">Type 3</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">No</td>
<td align="left" valign="top">No</td>
<td align="left" valign="top">Diffuse</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">Preauricular wrinkling and frontal vein prominence</td>
<td align="left" valign="top">FAPD</td>
</tr>
<tr>
<td align="left" valign="top">4</td>
<td align="center" valign="top">49</td>
<td align="center" valign="top">3</td>
<td align="left" valign="top">&#x2013;</td>
<td align="left" valign="top">Type 1</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">No</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">None</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">Facial papules</td>
<td align="left" valign="top">FAPD</td>
</tr>
<tr>
<td align="left" valign="top">5</td>
<td align="center" valign="top">57</td>
<td align="center" valign="top">10</td>
<td align="left" valign="top">&#x2013;</td>
<td align="left" valign="top">Type 1</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">No</td>
<td align="left" valign="top">Diffuse</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">Facial papules</td>
<td align="left" valign="top">Indeterminate</td>
</tr>
<tr>
<td align="left" valign="top">6</td>
<td align="center" valign="top">62</td>
<td align="center" valign="top">10</td>
<td align="left" valign="top">Hypothyroidism and genital lichen sclerosus</td>
<td align="left" valign="top">Type 1</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">Diffuse</td>
<td align="left" valign="top">No</td>
<td align="left" valign="top">Preauricular wrinkling</td>
<td align="left" valign="top">FAPD</td>
</tr>
<tr>
<td align="left" valign="top">7</td>
<td align="center" valign="top">56</td>
<td align="center" valign="top">8</td>
<td align="left" valign="top">&#x2013;</td>
<td align="left" valign="top">Type 2</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">No</td>
<td align="left" valign="top">No</td>
<td align="left" valign="top">Diffuse</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">Preauricular wrinkling and frontal vein prominence</td>
<td align="left" valign="top">CA-FFA</td>
</tr>
<tr>
<td align="left" valign="top">8</td>
<td align="center" valign="top">62</td>
<td align="center" valign="top">7</td>
<td align="left" valign="top">Breast cancer</td>
<td align="left" valign="top">Type 1</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">No</td>
<td align="left" valign="top">No</td>
<td align="left" valign="top">Diffuse</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">Preauricular wrinkling and extrafacial follicular red dots</td>
<td align="left" valign="top">CA-FFA</td>
</tr>
<tr>
<td align="left" valign="top">9</td>
<td align="center" valign="top">69</td>
<td align="center" valign="top">10</td>
<td align="left" valign="top">Rosacea</td>
<td align="left" valign="top">Type 2</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">No</td>
<td align="left" valign="top">Diffuse</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">Frontal vein prominence</td>
<td align="left" valign="top">CA-FFA</td>
</tr>
<tr>
<td align="left" valign="top">10</td>
<td align="center" valign="top">77</td>
<td align="center" valign="top">30</td>
<td align="left" valign="top">Psoriasis and hypothyroidism</td>
<td align="left" valign="top">Type 2</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">Diffuse</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">&#x2013;</td>
<td align="left" valign="top">CA-FFA</td>
</tr>
<tr>
<td align="left" valign="top">11</td>
<td align="center" valign="top">63</td>
<td align="center" valign="top">3</td>
<td align="left" valign="top">Hypothyroidism</td>
<td align="left" valign="top">Type 2</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">No</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">Diffuse</td>
<td align="left" valign="top">No</td>
<td align="left" valign="top">&#x2013;</td>
<td align="left" valign="top">FAPD</td>
</tr>
<tr>
<td align="left" valign="top">12</td>
<td align="center" valign="top">66</td>
<td align="center" valign="top">1</td>
<td align="left" valign="top">&#x2013;</td>
<td align="left" valign="top">Type 2</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">No</td>
<td align="left" valign="top">Diffuse</td>
<td align="left" valign="top">Yes</td>
<td align="left" valign="top">&#x2013;</td>
<td align="left" valign="top">Indeterminate</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><sup>&#x002A;</sup>Accompanying features grouped as present on clinical examination: facial papules, preauricular wrinkling, extrafacial follicular red dots, and frontal vein prominence.</p>
</table-wrap-foot>
</table-wrap>
<p>All patients underwent treatment prior to biopsy (<xref ref-type="table" rid="tab3">Table 3</xref>). All but one patient were on systemic therapy, with the vast majority receiving dutasteride (either as monotherapy or in combination). Additionally, seven patients were treated topically in the interparietal region with corticosteroids and/or 5% minoxidil. Treatment distribution was generally balanced across the study groups.</p>
<table-wrap position="float" id="tab3">
<label>Table 3</label>
<caption>
<p>Treatments at the time of biopsy.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Patient</th>
<th align="left" valign="top">Interparietal topical treatment</th>
<th align="left" valign="top">Frontal topical treatment</th>
<th align="left" valign="top">Systemic treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">1</td>
<td align="left" valign="top">Clobetasol, minoxidil, and finasteride</td>
<td align="left" valign="top">Clobetasol, minoxidil, and finasteride</td>
<td align="left" valign="top">Dutasteride and isotretinoin</td>
</tr>
<tr>
<td align="left" valign="top">2</td>
<td align="left" valign="top">Mometasone furoate</td>
<td align="left" valign="top">Mometasone furoate</td>
<td/>
</tr>
<tr>
<td align="left" valign="top">3</td>
<td/>
<td align="left" valign="top">Pimecrolimus</td>
<td align="left" valign="top">Dutasteride and minoxidil</td>
</tr>
<tr>
<td align="left" valign="top">4</td>
<td align="left" valign="top">Minoxidil</td>
<td align="left" valign="top">Pimecrolimus</td>
<td align="left" valign="top">Dutasteride</td>
</tr>
<tr>
<td align="left" valign="top">5</td>
<td align="left" valign="top">Mometasone furoate</td>
<td align="left" valign="top">Pimecrolimus and mometasone furoate</td>
<td align="left" valign="top">Dutasteride</td>
</tr>
<tr>
<td align="left" valign="top">6</td>
<td align="left" valign="top">Clobetasol</td>
<td align="left" valign="top">Pimecrolimus and clobetasol</td>
<td align="left" valign="top">Dutasteride and azithromycin</td>
</tr>
<tr>
<td align="left" valign="top">7</td>
<td/>
<td align="left" valign="top">Pimecrolimus</td>
<td align="left" valign="top">Dutasteride and isotretinoin</td>
</tr>
<tr>
<td align="left" valign="top">8</td>
<td/>
<td align="left" valign="top">Pimecrolimus</td>
<td align="left" valign="top">Minoxidil and isotretinoin</td>
</tr>
<tr>
<td align="left" valign="top">9</td>
<td align="left" valign="top">Minoxidil and finasteride</td>
<td align="left" valign="top">Pimecrolimus, minoxidil, and finasteride</td>
<td align="left" valign="top">Dutasteride</td>
</tr>
<tr>
<td align="left" valign="top">10</td>
<td align="left" valign="top">Clobetasol and minoxidil</td>
<td align="left" valign="top">Pimecrolimus, clobetasol, and minoxidil</td>
<td align="left" valign="top">Dutasteride and isotretinoin</td>
</tr>
<tr>
<td align="left" valign="top">11</td>
<td/>
<td/>
<td align="left" valign="top">Dutasteride and minoxidil</td>
</tr>
<tr>
<td align="left" valign="top">12</td>
<td align="left" valign="top">Clobetasol</td>
<td align="left" valign="top">Pimecrolimus and clobetasol</td>
<td align="left" valign="top">Dutasteride</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec sec-type="discussion" id="sec4">
<label>4</label>
<title>Discussion</title>
<p>After examining interparietal scalp biopsies from patients with a prior diagnosis of FFA who, on follow-up, developed clinical or trichoscopic evidence of inflammatory involvement in that region, we identified two main histopathologic patterns: CA-FFA and FAPD. CA-FFA was characterized by greater structural loss with reduced/absent sebaceous glands and occasional epithelial&#x2013;stromal clefting. In contrast, FAPD showed more vellus/miniaturized hairs and a shift of terminal follicles toward catagen/telogen, with comparatively milder architectural disruption. Patients with a biopsy suggestive of CA-FFA more often had a diffuse clinical pattern, which implies a worse prognosis, were older, had a longer disease duration, and had approximately twice as much occipital involvement as than those in the FAPD group.</p>
<p>Our results, together with prior observations that FFA causes a greater structural disruption than FAPD (<xref ref-type="bibr" rid="ref7">7</xref>), raise the question of whether FFA and FAPD represent overlapping entities, as already proposed by other authors, or whether they are part of the same process that has progressed (<xref ref-type="bibr" rid="ref8">8</xref>, <xref ref-type="bibr" rid="ref9">9</xref>). Familial occurrence of both FAPD and FFA has been reported in the literature (<xref ref-type="bibr" rid="ref10">10</xref>), and the presence in FAPD of features otherwise associated with FFA&#x2014;such as facial papules (<xref ref-type="bibr" rid="ref11">11</xref>) and/or extrafacial follicular red dots (<xref ref-type="bibr" rid="ref12">12</xref>)&#x2014;prompts us to consider if there is a common pathogenic pathway between both entities.</p>
<p>Furthermore, different authors have proposed considering both entities within a single spectrum. Du et al. described five patients with focal and diffuse fibrosing alopecia with overlapping features and a slowly progressive course (<xref ref-type="bibr" rid="ref8">8</xref>). However, in contrast to the findings of our study, they noted that younger patients had more evident thinning at the hairline and comparatively mild involvement at the crown, whereas older patients exhibited advanced thinning at both locations. Other authors have proposed that FFA and FAPD may represent the end of a continuum starting from AGA with histologic evidence of follicular microinflammation culminating in clinically noticeable forms of inflammatory cicatricial alopecia (<xref ref-type="bibr" rid="ref9">9</xref>). They have reported that this hypothesis is reinforced by the overlap of FFA, AGA, and FAPD observed in 11% of their patients, a hypothesis that would also be reinforced by our results.</p>
<p>Moreover, one study found no statistically significant difference in the presence of perifollicular inflammatory infiltrates in affected and unaffected areas of the scalp in patients with FFA (<xref ref-type="bibr" rid="ref13">13</xref>), while another study showed infundibular and isthmic perifollicular infiltrates in 88% of patients with AGA (<xref ref-type="bibr" rid="ref14">14</xref>). The reason why these infiltrates do not produce scarring alopecia is still unknown. A plausible explanation is that an as-yet unidentified antigenic stimulus from the damaged hair follicle may trigger a lichenoid tissue reaction in immunologically susceptible individuals (<xref ref-type="bibr" rid="ref9">9</xref>).</p>
<p>Our study has some limitations. First, the sample size was small, and we did not have a control group. Second, we did not characterize the non-inflammatory interparietal involvement of patients with FFA. Third, our patients underwent treatment prior to the biopsy, which might alter the histopathological results. We may have observed lower-dense inflammatory infiltrates due to the use of corticosteroids and other anti-inflammatory drugs, an increase in anagen follicles due to minoxidil, and a decrease in miniaturized hairs due to the use of 5-alpha-reductase inhibitors. These factors should be considered when interpreting our findings.</p>
</sec>
<sec sec-type="conclusions" id="sec5">
<label>5</label>
<title>Conclusion</title>
<p>To the best of our knowledge, we present the first study whose objective is to histopathologically characterize inflammatory interparietal involvement in patients with FFA, having found mainly two patterns. Patients with CA-FFA more frequently presented a diffuse clinical pattern, were older, and had a higher median evolution time than those belonging to the FAPD group.</p>
<p>Further studies in patients with FFA and FAPD are needed to elucidate the presumed role of androgenetic factors in addition to the lymphohistiocytic infiltrate and perifollicular lamellar fibrosis. It remains to be established whether differentiating between FFA and FAPD in the interparietal area may have prognostic and therefore therapeutic implications.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="sec6">
<title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec sec-type="ethics-statement" id="sec7">
<title>Ethics statement</title>
<p>Ethical approval was not required for the study involving humans in accordance with the local legislation and institutional requirements. Written informed consent to participate in this study was not required from the participants or the participants&#x2019; legal guardians/next of kin in accordance with the national legislation and the institutional requirements. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p>
</sec>
<sec sec-type="author-contributions" id="sec8">
<title>Author contributions</title>
<p>MG: Conceptualization, Investigation, Methodology, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing, Data curation. AR-V: Conceptualization, Investigation, Methodology, Data curation, Writing &#x2013; review &#x0026; editing. DV: Data curation, Writing &#x2013; review &#x0026; editing. MV: Conceptualization, Investigation, Methodology, Writing &#x2013; review &#x0026; editing. JR: Supervision, Writing &#x2013; review &#x0026; editing. AG: Conceptualization, Methodology, Supervision, Writing &#x2013; review &#x0026; editing.</p>
</sec>
<sec sec-type="COI-statement" id="sec9">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="sec10">
<title>Generative AI statement</title>
<p>The author(s) declared that Generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="sec11">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kossard</surname><given-names>S</given-names></name></person-group>. <article-title>Postmenopausal frontal fibrosing alopecia: scarring alopecia in a pattern distribution</article-title>. <source>Arch Dermatol</source>. (<year>1994</year>) <volume>130</volume>:<fpage>770</fpage>&#x2013;<lpage>4</lpage>. doi: <pub-id pub-id-type="doi">10.1001/archderm.1994.01690060100013</pub-id></mixed-citation></ref>
<ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Va&#x00F1;&#x00F3;-Galv&#x00E1;n</surname><given-names>S</given-names></name> <name><surname>Molina-Ruiz</surname><given-names>A</given-names></name> <name><surname>Serrano-Falc&#x00F3;n</surname><given-names>C</given-names></name> <name><surname>Arias-Santiago</surname><given-names>S</given-names></name> <name><surname>Rodrigues-Barata</surname><given-names>A</given-names></name> <name><surname>Garnacho-Saucedo</surname><given-names>G</given-names></name> <etal/></person-group>. <article-title>Frontal fibrosing alopecia: a multicenter review of 355 patients</article-title>. <source>J Am Acad Dermatol</source>. (<year>2014</year>) <volume>70</volume>:<fpage>670</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jaad.2013.12.003</pub-id>, <pub-id pub-id-type="pmid">24508293</pub-id></mixed-citation></ref>
<ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starace</surname><given-names>M</given-names></name> <name><surname>Orlando</surname><given-names>G</given-names></name> <name><surname>Alessandrini</surname><given-names>A</given-names></name> <name><surname>Baraldi</surname><given-names>C</given-names></name> <name><surname>Bruni</surname><given-names>F</given-names></name> <name><surname>Piraccini</surname><given-names>BM</given-names></name></person-group>. <article-title>Diffuse variants of scalp lichen planopilaris: clinical, trichoscopic, and histopathologic features of 40 patients</article-title>. <source>J Am Acad Dermatol</source>. (<year>2020</year>) <volume>83</volume>:<fpage>1659</fpage>&#x2013;<lpage>67</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jaad.2019.11.006</pub-id>, <pub-id pub-id-type="pmid">31706933</pub-id></mixed-citation></ref>
<ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanti</surname><given-names>V</given-names></name> <name><surname>Constantinou</surname><given-names>A</given-names></name> <name><surname>Reygagne</surname><given-names>P</given-names></name> <name><surname>Vogt</surname><given-names>A</given-names></name> <name><surname>Kottner</surname><given-names>J</given-names></name> <name><surname>Blume-Peytavi</surname><given-names>U</given-names></name></person-group>. <article-title>Frontal fibrosing alopecia: demographic and clinical characteristics of 490 cases</article-title>. <source>J Eur Acad Dermatol Venereol</source>. (<year>2019</year>) <volume>33</volume>:<fpage>1976</fpage>&#x2013;<lpage>83</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jdv.15735</pub-id>, <pub-id pub-id-type="pmid">31179579</pub-id></mixed-citation></ref>
<ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>A</given-names></name> <name><surname>Clark</surname><given-names>C</given-names></name> <name><surname>Holmes</surname><given-names>S</given-names></name></person-group>. <article-title>Frontal fibrosing alopecia: a review of 60 cases</article-title>. <source>J Am Acad Dermatol</source>. (<year>2012</year>) <volume>67</volume>:<fpage>955</fpage>&#x2013;<lpage>61</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jaad.2011.12.038</pub-id>, <pub-id pub-id-type="pmid">22503342</pub-id></mixed-citation></ref>
<ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakowska</surname><given-names>A</given-names></name> <name><surname>Wa&#x015B;kiel</surname><given-names>A</given-names></name> <name><surname>Sikora</surname><given-names>M</given-names></name> <name><surname>Olszewska</surname><given-names>M</given-names></name> <name><surname>Rudnicka</surname><given-names>L</given-names></name></person-group>. <article-title>Two different trichoscopic patterns of mid-frontal scalp in patients with frontal fibrosing alopecia and clinical features of androgenetic alopecia</article-title>. <source>Przegl Dermatol</source>. (<year>2017</year>) <volume>1</volume>:<fpage>9</fpage>&#x2013;<lpage>15</lpage>. doi: <pub-id pub-id-type="doi">10.5114/dr.2017.66217</pub-id>, <pub-id pub-id-type="pmid">41229260</pub-id></mixed-citation></ref>
<ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teixeira</surname><given-names>M</given-names></name> <name><surname>Gavazzoni Dias</surname><given-names>M</given-names></name> <name><surname>Vilar</surname><given-names>E</given-names></name> <name><surname>Pantale&#x00E3;o</surname><given-names>L</given-names></name> <name><surname>Jourdan</surname><given-names>R</given-names></name> <name><surname>Ekelem</surname><given-names>C</given-names></name> <etal/></person-group>. <article-title>Histopathological differential diagnosis of frontal fibrosing alopecia and fibrosing alopecia in a pattern distribution</article-title>. <source>Br J Dermatol</source>. (<year>2021</year>) <volume>185</volume>:<fpage>1069</fpage>&#x2013;<lpage>70</lpage>. doi: <pub-id pub-id-type="doi">10.1111/bjd.20592</pub-id>, <pub-id pub-id-type="pmid">34157130</pub-id></mixed-citation></ref>
<ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>X</given-names></name> <name><surname>Li</surname><given-names>Y</given-names></name> <name><surname>Zhu</surname><given-names>Q</given-names></name> <name><surname>Zhu</surname><given-names>J</given-names></name> <name><surname>Xu</surname><given-names>W</given-names></name> <name><surname>Li</surname><given-names>Z</given-names></name> <etal/></person-group>. <article-title>Focal and diffuse fibrosing alopecias: classical lichen planopilaris, frontal fibrosing alopecia, fibrosing alopecia with a pattern distribution, cicatricial pattern hair loss, and lichen planopilaris diffuse pattern</article-title>. <source>JAAD Case Rep</source>. (<year>2020</year>) <volume>6</volume>:<fpage>32382630</fpage>:<fpage>403</fpage>&#x2013;<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jdcr.2020.02.036</pub-id></mixed-citation></ref>
<ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katoulis</surname><given-names>A</given-names></name> <name><surname>Diamanti</surname><given-names>K</given-names></name> <name><surname>Sgouros</surname><given-names>D</given-names></name> <name><surname>Liakou</surname><given-names>A</given-names></name> <name><surname>Bozi</surname><given-names>E</given-names></name> <name><surname>Avgerinou</surname><given-names>G</given-names></name> <etal/></person-group>. <article-title>Is there a pathogenetic link between frontal fibrosing alopecia, androgenetic alopecia and fibrosing alopecia in a pattern distribution?</article-title> <source>J Eur Acad Dermatol Venereol</source>. (<year>2018</year>) <volume>32</volume>:<fpage>218</fpage>&#x2013;<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jdv.14748</pub-id>, <pub-id pub-id-type="pmid">29224248</pub-id></mixed-citation></ref>
<ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Missio</surname><given-names>D</given-names></name> <name><surname>Dias</surname><given-names>M</given-names></name> <name><surname>Tr&#x00FC;eb</surname><given-names>RM</given-names></name></person-group>. <article-title>Familial cicatricial alopecia: report of familial frontal fibrosing alopecia and fibrosing alopecia in a pattern distribution</article-title>. <source>Int J Trichology</source>. (<year>2017</year>) <volume>9</volume>:<fpage>130</fpage>&#x2013;<lpage>4</lpage>. doi: <pub-id pub-id-type="doi">10.4103/ijt.ijt_59_17</pub-id>, <pub-id pub-id-type="pmid">28932068</pub-id></mixed-citation></ref>
<ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramanauskaite</surname><given-names>A</given-names></name> <name><surname>Tr&#x00FC;eb</surname><given-names>RM</given-names></name></person-group>. <article-title>Facial papules in fibrosing alopecia in a pattern distribution (cicatricial pattern hair loss)</article-title>. <source>Int J Trichol</source>. (<year>2015</year>) <volume>7</volume>:<fpage>119</fpage>&#x2013;<lpage>22</lpage>. doi: <pub-id pub-id-type="doi">10.4103/0974-7753.167463</pub-id>, <pub-id pub-id-type="pmid">26622155</pub-id></mixed-citation></ref>
<ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Billero</surname><given-names>V</given-names></name> <name><surname>Oberlin</surname><given-names>K</given-names></name> <name><surname>Miteva</surname><given-names>M</given-names></name></person-group>. <article-title>Red dots in a net-like pattern on the upper chest: a novel clinical observation in frontal fibrosing alopecia and fibrosing alopecia in pattern distribution</article-title>. <source>Skin Appendage Disord</source>. (<year>2018</year>) <volume>4</volume>:<fpage>47</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000478947</pub-id>, <pub-id pub-id-type="pmid">29457016</pub-id></mixed-citation></ref>
<ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pindado-Ortega</surname><given-names>C</given-names></name> <name><surname>Perna</surname><given-names>C</given-names></name> <name><surname>Saceda-Corralo</surname><given-names>D</given-names></name> <name><surname>Fern&#x00E1;ndez-Nieto</surname><given-names>D</given-names></name> <name><surname>Ja&#x00E9;n-Olasolo</surname><given-names>P</given-names></name> <name><surname>Va&#x00F1;&#x00F3;-Galv&#x00E1;n</surname><given-names>S</given-names></name></person-group>. <article-title>Frontal fibrosing alopecia: histopathological, immunohistochemical and hormonal study of clinically unaffected scalp areas</article-title>. <source>J Eur Acad Dermatol Venereol</source>. (<year>2020</year>) <volume>34</volume>:<fpage>84</fpage>&#x2013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1111/jdv.15977</pub-id>, <pub-id pub-id-type="pmid">31566821</pub-id></mixed-citation></ref>
<ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plante</surname><given-names>J</given-names></name> <name><surname>Valdebran</surname><given-names>M</given-names></name> <name><surname>Forcucci</surname><given-names>J</given-names></name> <name><surname>Lucas</surname><given-names>O</given-names></name> <name><surname>Elston</surname><given-names>DM</given-names></name></person-group>. <article-title>Perifollicular inflammation and follicular spongiosis in androgenetic alopecia</article-title>. <source>J Am Acad Dermatol</source>. (<year>2022</year>) <volume>86</volume>:<fpage>437</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jaad.2021.09.040</pub-id>, <pub-id pub-id-type="pmid">34587554</pub-id></mixed-citation></ref>
</ref-list>
<fn-group>
<fn fn-type="custom" custom-type="edited-by" id="fn0001">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1319234/overview">Ruano Juan</ext-link>, University of Cordoba, C&#x00F3;rdoba, Spain</p>
</fn>
<fn fn-type="custom" custom-type="reviewed-by" id="fn0002">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1663209/overview">Ricardo Ruiz-Villaverde</ext-link>, San Cecilio University Hospital, Granada, Spain</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2211810/overview">David Saceda Corralo</ext-link>, Hospital Ram&#x00F3;n y Cajal, Madrid, Spain</p>
</fn>
</fn-group>
</back>
</article>